BACKGROUND: Antibiotic overuse in the primary care setting is common. Our objective was to evaluate the effect of a clinical pathway-based intervention on antibiotic use. METHODS:Eight primary care clinics were randomized to receive clinical pathways for upper respiratory infection, acute bronchitis, acute rhinosinusitis, pharyngitis, acute otitis media, urinary tract infection, skin infections, and pneumonia and patient education materials (study group) versus no intervention (control group). Generalized linear mixed effects models were used to assess trends in antibiotic prescriptions for non-pneumonia acute respiratory infections and broad-spectrum antibiotic use for all 8 conditions during a 2-year baseline and 1-year intervention period. RESULTS: In the study group, antibiotic prescriptions for non-pneumonia acute respiratory infections decreased from 42.7% of cases at baseline to 37.9% during the intervention period (11.2% relative reduction) (P<.0001) and from 39.8% to 38.7%, respectively, in the control group (2.8% relative reduction) (P=.25). Overall use of broad-spectrum antibiotics in the study group decreased from 26.4% to 22.6% of cases, respectively (14.4% relative reduction) (P<.0001) and from 20.0% to 19.4%, respectively, in the control group (3.0% relative reduction) (P=.35). There were significant differences in the trends of prescriptions for acute respiratory infections (P<.0001) and broad-spectrum antibiotic use (P=.001) between the study and control groups during the intervention period, with greater declines in the study group. CONCLUSIONS: This intervention was associated with declining antibiotic prescriptions for non-pneumonia acute respiratory infections and use of broad-spectrum antibiotics over the first year. Evaluation of the impact over a longer study period is warranted.
RCT Entities:
BACKGROUND: Antibiotic overuse in the primary care setting is common. Our objective was to evaluate the effect of a clinical pathway-based intervention on antibiotic use. METHODS: Eight primary care clinics were randomized to receive clinical pathways for upper respiratory infection, acute bronchitis, acute rhinosinusitis, pharyngitis, acute otitis media, urinary tract infection, skin infections, and pneumonia and patient education materials (study group) versus no intervention (control group). Generalized linear mixed effects models were used to assess trends in antibiotic prescriptions for non-pneumonia acute respiratory infections and broad-spectrum antibiotic use for all 8 conditions during a 2-year baseline and 1-year intervention period. RESULTS: In the study group, antibiotic prescriptions for non-pneumonia acute respiratory infections decreased from 42.7% of cases at baseline to 37.9% during the intervention period (11.2% relative reduction) (P<.0001) and from 39.8% to 38.7%, respectively, in the control group (2.8% relative reduction) (P=.25). Overall use of broad-spectrum antibiotics in the study group decreased from 26.4% to 22.6% of cases, respectively (14.4% relative reduction) (P<.0001) and from 20.0% to 19.4%, respectively, in the control group (3.0% relative reduction) (P=.35). There were significant differences in the trends of prescriptions for acute respiratory infections (P<.0001) and broad-spectrum antibiotic use (P=.001) between the study and control groups during the intervention period, with greater declines in the study group. CONCLUSIONS: This intervention was associated with declining antibiotic prescriptions for non-pneumonia acute respiratory infections and use of broad-spectrum antibiotics over the first year. Evaluation of the impact over a longer study period is warranted.
Authors: J M Grimshaw; L Shirran; R Thomas; G Mowatt; C Fraser; L Bero; R Grilli; E Harvey; A Oxman; M A O'Brien Journal: Med Care Date: 2001-08 Impact factor: 2.983
Authors: Christianne L Roumie; Natasha B Halasa; Kathryn M Edwards; Yuwei Zhu; Robert S Dittus; Marie R Griffin Journal: Am J Med Date: 2005-06 Impact factor: 4.965
Authors: Jennifer K Maratt; Eve A Kerr; Mandi L Klamerus; Shannon E Lohman; Whit Froehlich; R Sacha Bhatia; Sameer D Saini Journal: J Gen Intern Med Date: 2019-06-27 Impact factor: 5.128
Authors: Rakesh D Mistry; Jason G Newland; Jeffrey S Gerber; Adam L Hersh; Larissa May; Sarah M Perman; Nathan Kuppermann; Peter S Dayan Journal: Infect Control Hosp Epidemiol Date: 2017-02-08 Impact factor: 3.254
Authors: Sara C Keller; Pranita D Tamma; Sara E Cosgrove; Melissa A Miller; Heather Sateia; Julie Szymczak; Ayse P Gurses; Jeffrey A Linder Journal: J Am Board Fam Med Date: 2018 May-Jun Impact factor: 2.657
Authors: Yorgo Zahlanie; Norman S Mang; Kevin Lin; Linda S Hynan; Bonnie C Prokesch Journal: Open Forum Infect Dis Date: 2020-12-21 Impact factor: 3.835
Authors: Daniele Donà; Silvia Zingarella; Andrea Gastaldi; Rebecca Lundin; Giorgio Perilongo; Anna Chiara Frigo; Rana F Hamdy; Theoklis Zaoutis; Liviana Da Dalt; Carlo Giaquinto Journal: PLoS One Date: 2018-02-28 Impact factor: 3.240